GeoVax Labs

Q2 FY2026 EarningsQ2 FY2026 results were better than expected in terms of bottom-line loss, with a net loss of $4.4M vs. the $5.3M consensus. Revenue was in-line at zero following the termination of the BARDA contract in 2025. GAAP EPS of -$0.97 significantly beat the -$2.16 consensus, driven by aggressive cost-cutting in R&D and G&A. Management confirmed the pivotal GEO-MVA immunobridging study remains on track for a Q4 2026 initiation.